MCID: RNL015
MIFTS: 45

Renal Hypertension

Categories: Cardiovascular diseases, Ear diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Hypertension

MalaCards integrated aliases for Renal Hypertension:

Name: Renal Hypertension 12 73 15 17 70
Hypertension, Renal 44
Hypertension Renal 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1073
MeSH 44 D006977
NCIt 50 C3121
SNOMED-CT 67 194775007
UMLS 70 C0020544

Summaries for Renal Hypertension

MalaCards based summary : Renal Hypertension, also known as hypertension, renal, is related to chronic pyelonephritis and perinephritis. An important gene associated with Renal Hypertension is EDN1 (Endothelin 1), and among its related pathways/superpathways are Pathways in cancer and Development Angiotensin activation of ERK. The drugs Bisoprolol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renal Hypertension

Diseases in the Renal Hypertension family:

Renal Failure, Progressive, with Hypertension

Diseases related to Renal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 chronic pyelonephritis 30.8 REN ALB ACE
2 perinephritis 30.6 REN EDN1 ACE
3 renovascular hypertension 30.5 REN NPPB NOS3 EDN1 AGTR1 ADM
4 uremia 30.5 REN EPO ALB ACE
5 proteinuria, chronic benign 30.5 REN APOL1 ALB AGTR1 ACE
6 fibromuscular dysplasia 30.4 REN AGTR1 AGT ACE
7 acute kidney failure 30.4 REN KNG1 ALB
8 pure autonomic failure 30.4 REN EPO DBH ACE
9 glomerulonephritis 30.4 MYH9 APOL1 ALB AGTR1 ACE
10 malignant hypertension 30.3 REN NPPB EDN1 AGTR1 AGT ADM
11 atherosclerosis susceptibility 30.2 NOS3 EDN1 ALB AGTR1 ACE
12 microvascular complications of diabetes 3 30.2 REN ALB AGTR1 ACE
13 hypertensive encephalopathy 30.1 REN EPO EDN1 ALB AGTR1 ACE
14 malignant renovascular hypertension 30.1 REN EDN1 AGTR1
15 coronary stenosis 30.1 NPPB ALB ACE
16 pheochromocytoma 30.1 REN KNG1 EPO EDN1 DBH ADM
17 urinary tract obstruction 30.0 REN ALB ACE
18 benign essential hypertension 30.0 REN ALB
19 hypokalemia 30.0 SLC12A3 REN ALB ACE
20 gitelman syndrome 30.0 SLC12A3 REN AGT
21 peripheral vascular disease 29.9 KNG1 EPO ALB ACE
22 renal dysplasia 29.8 REN AGTR1 AGT ACE
23 vascular disease 29.7 REN NPPB NOS3 KNG1 EPO EDN1
24 renal fibrosis 29.7 REN MIR200B ALB AGTR1 AGT
25 polycystic kidney disease 29.5 REN NOS3 EPO EDN1 ALB AGTR1
26 eclampsia 29.5 REN NOS3 EDN1 ALB AGT ACE
27 diastolic heart failure 29.4 REN NPPB NOS3 AGTR1 AGT ACE
28 autosomal dominant polycystic kidney disease 29.3 REN NOS3 EDN1 ALB AGTR1 AGT
29 pulmonary hypertension 29.3 REN NPPB NOS3 EDN1 ALB AGTR1
30 sleep apnea 29.3 REN NPPB NOS3 EPO EDN1 ALB
31 pre-eclampsia 29.2 REN NOS3 KNG1 EDN1 ALB AGTR1
32 congestive heart failure 29.0 REN NPPB NOS3 KNG1 EPO EDN1
33 end stage renal disease 28.9 REN NPPB NOS3 MYH9 EPO APOL1
34 hypertension, essential 28.9 SLC12A3 REN NPPB NOS3 MYH9 KNG1
35 kidney disease 28.8 SLC12A3 REN NPPB NOS3 MYH9 MIR200A
36 chronic kidney disease 28.8 REN NPPB NOS3 MYH9 EPO EDN1
37 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 11.7
38 polycystic kidney disease 4 with or without polycystic liver disease 10.9
39 polycystic kidney disease 3 with or without polycystic liver disease 10.9
40 c3 glomerulopathy 3 10.9
41 stress polycythemia 10.5 EPO ALB
42 cardiac tuberculosis 10.4 NPPB ACE
43 microvascular complications of diabetes 2 10.4 EPO ACE
44 chronic thromboembolic pulmonary hypertension 10.4 NPPB EDN1
45 polycystic kidney disease 4 10.4 NPPB ALB
46 renal artery obstruction 10.4 REN ACE
47 hypoaldosteronism 10.4 REN ACE
48 toxic myocarditis 10.4 NPPB ACE
49 pericarditis 10.4 NPPB ALB ACE
50 acute pulmonary heart disease 10.4 REN NPPB

Graphical network of the top 20 diseases related to Renal Hypertension:



Diseases related to Renal Hypertension

Symptoms & Phenotypes for Renal Hypertension

MGI Mouse Phenotypes related to Renal Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE ADM AGT AGTR1 ALB DBH
2 homeostasis/metabolism MP:0005376 9.83 ACE ADM AGT AGTR1 ALB DBH
3 renal/urinary system MP:0005367 9.32 ACE ADM AGT AGTR1 ALB EDN1

Drugs & Therapeutics for Renal Hypertension

Drugs for Renal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bisoprolol Approved Phase 4 66722-44-9 2405
2
Amlodipine Approved Phase 4 88150-42-9 2162
3 Antihypertensive Agents Phase 4
4 Vasodilator Agents Phase 4
5 Adrenergic Antagonists Phase 4
6 Adrenergic beta-Antagonists Phase 4
7 Adrenergic beta-1 Receptor Antagonists Phase 4
8 Hormones Phase 4
9 Adrenergic Agents Phase 4
10 Neurotransmitter Agents Phase 4
11 calcium channel blockers Phase 4
12 Calcium, Dietary Phase 4
13 Sympatholytics Phase 4
14
Calcium Nutraceutical Phase 4 7440-70-2 271
15
Ramipril Approved Phase 2, Phase 3 87333-19-5 5362129
16
Diltiazem Approved, Investigational Phase 2, Phase 3 42399-41-7 39186
17
Hydralazine Approved Phase 2, Phase 3 86-54-4 3637
18
rituximab Approved Phase 2 174722-31-7 10201696
19
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
20 Immunoglobulins Phase 2
21 Antibodies Phase 2
22 Antineoplastic Agents, Immunological Phase 2
23 Antirheumatic Agents Phase 2
24 Immunologic Factors Phase 2
25 Immunosuppressive Agents Phase 1, Phase 2
26 Anti-Bacterial Agents Phase 1, Phase 2
27 Antibiotics, Antitubercular Phase 1, Phase 2
28 Antitubercular Agents Phase 1, Phase 2
29 Anti-Infective Agents Phase 1, Phase 2
30 Anticoagulants
31 Liver Extracts

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. Completed NCT04085562 Phase 4 Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg
2 African American Study of Kidney Disease and Hypertension ABPM Pilot Study Completed NCT00582777 Phase 2, Phase 3 ADD On Dosing
3 The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant Completed NCT00446459 Phase 2 mycophenolate mofetil (CellCept)
4 The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Completed NCT00446251 Phase 2 Rituximab;Mycophenolate mofetil (MMF)
5 Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF) Recruiting NCT02432339 Phase 1, Phase 2 mycophenolate mofetil (MMF);Placebo
6 A Prospective, Multi-Center, Non-Randomized Feasibility Study of Catheter-Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02) Completed NCT01756300 Phase 1
7 A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157) Completed NCT02095691 Phase 1
8 Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used? Completed NCT02858518
9 Electroacupuncture for Hypertension Patients With Chronic Kidney Disease Completed NCT01766427
10 Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension (RENAL HIT Study) Completed NCT01549444
11 A Clinical Trial to Assess the Safety and Efficacy of the RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Suboptimal Post-procedural Percutaneous Transluminal Angioplasty (PTA) in de Novo or Restenotic Renal Artery Stenoses in Patients With Uncontrolled Hypertension. Completed NCT00490841
12 Clinical Outcome of Patients With Resistant Hypertension Undergoing Renal Denervation: A Report From the Swedish Registry for Renal Denervation Recruiting NCT04722159
13 Effectiveness of Implementation of a Patient-centered Self-management Program in Patients With Hypertensive Nephropathy Recruiting NCT04633993

Search NIH Clinical Center for Renal Hypertension

Cochrane evidence based reviews: hypertension, renal

Genetic Tests for Renal Hypertension

Anatomical Context for Renal Hypertension

MalaCards organs/tissues related to Renal Hypertension:

40
Kidney, Heart, Liver, Endothelial, Brain, Cortex, Smooth Muscle

Publications for Renal Hypertension

Articles related to Renal Hypertension:

(show top 50) (show all 3254)
# Title Authors PMID Year
1
[Management of renal atrophy in hypertensive patients: experience in Lille]. 61 54
19854024 2010
2
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. 54 61
16982943 2006
3
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. 61 54
16168275 2005
4
Association study of calcitonin-receptor-like receptor gene in essential hypertension. 54 61
15797661 2005
5
The clinical use of angiotensin-converting enzyme inhibitors. 61 54
15586352 2004
6
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? 54 61
12437489 2002
7
Methods for assessing endothelin ETA-receptor antagonists in preclinical studies. 61 54
12224443 2002
8
Endothelin and heart failure. 61 54
11447308 2001
9
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. 61 54
11675775 2001
10
Development of ideas on renovascular hypertension. 54 61
11022890 2000
11
[The protection of renal function in the ACEI treatment of renal hypertension]. 54 61
12206011 2000
12
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 54 61
10604545 1999
13
[Adrenomedullin]. 54 61
10352550 1999
14
[Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function]. 61 54
12080656 1999
15
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. 54 61
9796839 1998
16
Endothelin as a regulator of cardiovascular function in health and disease. 54 61
9794709 1998
17
Adrenomedullin: a new hypotensive peptide. 61 54
9120666 1996
18
Adrenomedullin: a new modulator of vascular tone. 54 61
8951571 1996
19
[Arterial hypertension in patients on chronic hemodialysis]. 54 61
9102857 1996
20
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. 54 61
8743512 1996
21
[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. 61 54
8686202 1996
22
Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. 61 54
8846416 1995
23
Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. 54 61
7473533 1995
24
[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]. 54 61
7638769 1995
25
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. 61 54
8143425 1994
26
Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. 54 61
8485747 1993
27
Urinary kallikrein excretion is low in malignant essential hypertension. 54 61
1325521 1992
28
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 54 61
1908620 1991
29
COVID-19 in Adults With Congenital Heart Disease. 61
33795039 2021
30
Novel SARS2 variants identified in a Chinese girl with HUPRA syndrome. 61
33751860 2021
31
Autosomal Recessive Polycystic Kidney Disease-The Clinical Aspects and Diagnostic Challenges. 61
33552631 2021
32
COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. 61
33646505 2021
33
Inhibition of L-NAME-induced hypertension by combined treatment with apocynin and catalase: the role of Nox 4 expression. 61
33728924 2021
34
Perceptions among Muslims regarding fasting, medication use and provider engagement during Ramadan in the United States. 61
33711183 2021
35
Native nephrectomy in the management of hypertension in children with kidney disease: a tool to improve blood pressure control. 61
33683431 2021
36
Resumé of the challenges and burden of living with transplanted hearts for >31 years. 61
33708489 2021
37
Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. 61
32633141 2021
38
A Positive Cocaine Urine Toxicology Test and the Effect on Intraoperative Hemodynamics Under General Anesthesia. 61
32304462 2021
39
Renal metabolism and hypertension. 61
33574248 2021
40
Risk factors for readmission with dehydration after ileostomy formation: A systematic review and meta-analysis. 61
33539646 2021
41
Changes in sympathetic nervous system activity after renal denervation: results from the randomised Oslo RDN study. 61
33399016 2021
42
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. 61
33393699 2021
43
Medical history of nocturnal enuresis during school age is an independent risk factor for nocturia in adults: The Nagahama study. 61
33118643 2021
44
Effects of catheter-based renal denervation on glycemic control and lipid levels: a systematic review and meta-analysis. 61
33459896 2021
45
Spontaneous Neuronal Plasticity in the Contralateral Motor Cortex and Corticospinal Tract after Focal Cortical Infarction in Hypertensive Rats. 61
32992200 2020
46
Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). 61
33310863 2020
47
Correlations between indices of dynamic components of ambulatory blood pressure and renal damage in elderly Chinese male with essential hypertension. 61
32769403 2020
48
Biclonal gammopathay in a case of severe COVID-19. 61
33159954 2020
49
Pregnancy outcomes amongst adolescents/young adults at tertiary-care hospital in a low-middle-income country: Ten-year retrospective record review. 61
33475588 2020
50
Development and Internal Validation of A Prediction Tool To Assist Clinicians Selecting Second-Line Therapy Following Metformin Monotherapy For Type 2 Diabetes. 61
33685669 2020

Variations for Renal Hypertension

Expression for Renal Hypertension

Search GEO for disease gene expression data for Renal Hypertension.

Pathways for Renal Hypertension

Pathways related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.62 KNG1 EPO EDN1 AGTR1 AGT
2
Show member pathways
12.59 NOS3 EPO EDN1 AGTR1 AGT
3
Show member pathways
12.27 NPPB NOS3 KNG1 AGTR1 AGT
4
Show member pathways
11.96 NPPB NOS3 MYH9 EDN1 AGTR1 AGT
5 11.62 NOS3 EDN1 AGTR1 AGT
6 11.47 EPO EDN1 ADM
7 11.39 REN EDN1 AGTR1 AGT ACE
8 11.37 NOS3 EPO EDN1
9 11.21 MIR200B MIR200A MIR141
10
Show member pathways
11 REN NOS3 KNG1 AGTR1 AGT ACE
11 10.79 GPR182 DBH ADM

GO Terms for Renal Hypertension

Cellular components related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 REN NPPB KNG1 KLKB1 EPO EDN1
2 blood microparticle GO:0072562 9.46 KNG1 APOL1 ALB AGT
3 extracellular space GO:0005615 9.44 REN NPPB MIR141 KNG1 KLKB1 EPO

Biological processes related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.01 MIR200B MIR141 EPO EDN1 AGT ADM
2 kidney development GO:0001822 9.85 REN AGTR1 AGT ACE
3 response to lipopolysaccharide GO:0032496 9.85 REN NOS3 EPO EDN1 ADM
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.8 KNG1 EDN1 AGTR1 AGT ADM
5 blood vessel remodeling GO:0001974 9.67 NOS3 DBH AGT ACE
6 vasodilation GO:0042311 9.65 NOS3 KNG1 AGT
7 positive regulation of cellular protein metabolic process GO:0032270 9.63 AGTR1 AGT
8 amyloid-beta metabolic process GO:0050435 9.63 REN ACE
9 positive regulation of urine volume GO:0035810 9.62 NPPB EDN1
10 negative regulation of blood coagulation GO:0030195 9.62 KNG1 EDN1
11 angiotensin maturation GO:0002003 9.61 REN ACE
12 artery smooth muscle contraction GO:0014824 9.61 EDN1 AGT
13 positive regulation of renal sodium excretion GO:0035815 9.61 NPPB EDN1 AGT
14 response to dexamethasone GO:0071548 9.6 EPO EDN1
15 positive regulation of cholesterol esterification GO:0010873 9.59 AGTR1 AGT
16 body fluid secretion GO:0007589 9.58 NPPB EDN1
17 positive regulation of NAD(P)H oxidase activity GO:0033864 9.58 AGTR1 AGT
18 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.57 NOS3 EDN1
19 regulation of renal sodium excretion GO:0035813 9.56 AGTR1 AGT
20 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.52 AGTR1 AGT
21 regulation of renal output by angiotensin GO:0002019 9.51 AGT ACE
22 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.5 AGTR1 AGT ACE
23 regulation of blood volume by renin-angiotensin GO:0002016 9.49 REN AGT
24 regulation of blood vessel diameter GO:0097746 9.46 NPPB NOS3 AGTR1 ACE
25 renin-angiotensin regulation of aldosterone production GO:0002018 9.43 REN AGTR1 AGT
26 regulation of vasoconstriction GO:0019229 9.26 EDN1 AGTR1 AGT ACE
27 regulation of blood pressure GO:0008217 9.1 REN NPPB NOS3 EDN1 AGT ACE

Molecular functions related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 REN NPPB KNG1 EDN1 ADM
2 hormone activity GO:0005179 9.02 NPPB EPO EDN1 AGT ADM
3 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Renal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....